Adhera Therapeutics, Inc. - FORM 10-Q - EX-10.2 - AMENDMENT NO. 1, DATED OCTOBER 9, 2008 - August 12, 2010

Attached files

file filename
10-Q - FORM 10-Q - Adhera Therapeutics, Inc.d10q.htm
EX-10.4 - AMENDMENT NO. 3 DATED JUNE 4, 2010 - Adhera Therapeutics, Inc.dex104.htm
EX-10.5 - FIRST AMENDMENT, DATED AS OF JANUARY 29, 2009 - Adhera Therapeutics, Inc.dex105.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - Adhera Therapeutics, Inc.dex312.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - Adhera Therapeutics, Inc.dex322.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - Adhera Therapeutics, Inc.dex311.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - Adhera Therapeutics, Inc.dex321.htm
EX-10.3 - AMENDMENT NO. 2, DATED JUNE 18, 2009 - Adhera Therapeutics, Inc.dex103.htm
EX-10.1 - PATENT ASSIGNMENT AND LICENSE AGREEMENT, DATED MAY 21, 2008 - Adhera Therapeutics, Inc.dex101.htm

Exhibit 10.2

Amendment No. 1, dated October 9, 2008, to a certain Patent Assignment And License Agreement, dated May 21, 2008 (the “Agreement”), by and between Ribotask ApS, having its offices at Søndre Boulevard 44, 3, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).

WHEREAS, the parties wish to modify the schedule of payments to be made under Section 3.2.1 of the Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants set forth herein, the parties hereto hereby agree as follows:

1. The payment schedule set forth in Section 3.2.1 of the Agreement is hereby modified in its entirety as follows:

 

Date

    Amount  

Execution of Definitive Agreement

    $ 50,000  (paid) 

August 1, 2008

    $ 50,000  (paid) 

Execution of Amendment No. 1

    $ 100,000   

December 30, 2008

    $ 100,000   

February 1, 2009

    $ 200,000   

2. Except as specifically modified by this Amendment No. 1, all provisions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be duly executed as of the day and year first above written.

 

ASSIGNOR:

 

Ribotask ApS

 

     

ASSIGNEE:

 

MDRNA, Inc.

 

By:  

/s/ Jesper Wengel

      By:  

Bruce R. York

       Name: Jesper Wengel, Ph.D.          Name: Bruce R. York
       Title: Chairman of the Board          Title: CFO
By:  

/s/ Suzy Lena

       
       Name: Suzy Lena       
       Title: CEO       

Adhera Therapeutics, Inc. Reports